论文部分内容阅读
目的探讨重型病毒性肝炎分期多环节药物治疗效果。方法依据重型病毒性肝炎的发病机理进行分期多环节药物综合治疗、在病程早期，采用抑制强烈的免疫反应、阻断肠源性内毒素血症和以肿瘤坏死因子为核心的细胞因子网络、改善肝内微循环、保护肝细胞、消除反应氧中间产物、促进肝细胞再生及高价营养疗法；在病程中晚期，禁用免疫抑制剂。用本方案治疗了321例重型病毒性肝炎。结果重型病毒性肝炎早期病例的治疗有效率（84．21％）明显高于中期（55．55％）和晚期（8．77％）病例（P值均＜0．005），中期病例亦明显高于晚期病例（P＜0．005）．结论对重型病毒性肝炎进行分期多环节药物治疗是合理和必要的。在重型肝炎早期进行积极救洽，防止向中晚期发展，可显著降低重型肝炎的总体病死率。报告分期治疗效果有利于各家报道之间的比较。
Objective To investigate the effect of staged and multiple drug treatment in patients with severe viral hepatitis. Methods According to the pathogenesis of severe viral hepatitis, the patients were treated with phased and multiphasic drug combination therapy. In the early course of the disease, the inhibition of gut endotoxemia and tumor necrosis factor-mediated cytokine network were improved Intrahepatic microcirculation, protect liver cells, eliminate reactive oxygen intermediates, promote liver cell regeneration and high-priced nutrition therapy; immunosuppressants are banned in the late course of the disease. With this program, 321 cases of severe viral hepatitis were treated. Results The effective rate of early treatment of severe viral hepatitis (84.21%) was significantly higher than that of intermediate stage (55.55%) and advanced stage (8.77%) (all P <0.005) Higher than the late cases (P <0.005). Conclusion It is reasonable and necessary to carry out staged and multiphasic drug therapy for severe viral hepatitis. Active rescue in severe hepatitis early to prevent the development of the late, can significantly reduce the overall mortality of severe hepatitis. The report staging treatment is conducive to the comparison between various reports.